IDEAYA Biosciences to Engage Investors at Major Conferences in December 2025

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a forefront player in precision medicine oncology, has made an announcement regarding its participation in significant investor relations events scheduled for December 2025. The company is committed to discovering and developing targeted therapies, and these upcoming conferences will provide a crucial platform for engaging with investors to communicate their innovative strategies and future directions.

Event Details

IDEAYA will be actively participating in two key events:

1. Citi's 2025 Global Healthcare Conference
Date: Tuesday, December 2, 2025
Time: 9:00 AM ET
This event will feature a fireside chat with Yujiro S. Hata, the President and CEO of IDEAYA. The discussion will be hosted by Yigal D. Nochomovitz, Ph.D., who is a recognized director and analyst in the fields of small and mid-cap biotechnology.

2. 8th Annual Evercore Healthcare Conference
Date: Wednesday, December 3, 2025
Time: 10:50 AM ET
During this event, another fireside chat will take place with Yujiro S. Hata, under the moderation of Jonathan Miller, the Managing Director specializing in biotech and pharmaceutical equity research.

For those unable to attend the live sessions, IDEAYA will provide a live audio webcast during the events, which can be accessed through the Investors/Events section of their official website. In addition, recorded versions of the webcasts will be available for 30 days post-event, allowing wider access to the insights shared during the sessions.

About IDEAYA Biosciences

Founded with a commitment to oncology, IDEAYA Biosciences is leading the charge in precision medicine by focusing on the discovery, development, and commercialization of transformative cancer therapies. Utilizing an integrated approach that fuses small-molecule drug discovery, structural biology, and bioinformatics, IDEAYA is at the forefront of creating pioneering treatments that target the genetic drivers of various cancers.

The company's product pipeline is robust, featuring candidates designed around principles of synthetic lethality, as well as unique antibody-drug conjugates (ADCs) aimed at treating molecularly-defined solid tumor indications. The ultimate goal of IDEAYA is to revolutionize cancer treatment through innovative drugs that are not only more selective and effective but also tailored to meet the individual needs of patients.

In addition to discussing their upcoming investor events, IDEAYA recognizes the inherent risks and uncertainties involved in the biotechnology field, which can impact actual outcomes. The company provides updates and disclosures through its filings with the U.S. Securities and Exchange Commission to ensure transparency with stakeholders.

Conclusion

IDEAYA Biosciences is poised to provide meaningful insights and strategic updates during its participation in the anticipated investor relations events in December. Their commitment to pioneering oncology therapies aligns closely with their mission of improving clinical outcomes for patients facing cancer. As these conferences approach, IDEAYA's communications will be crucial not only for investors but also for all stakeholders interested in the future of cancer treatment.

For further information on IDEAYA's latest developments, interested parties are encouraged to visit the IDEAYA Biosciences official website.